InDex Pharmaceuticals Holding AB (publ) interim report January – June 2017
First patient enrolled in the CONDUCT studyPeriod April – June 2017 · Revenues amounted to SEK 0.0 (0.1) million · Operating result amounted to SEK –15.4 (–9.6) million · Result after tax amounted to SEK –15.2 (–10.5) million, corresponding to SEK –0.24 per share (–0.35) before and after dilution · Cash flow from operating activities amounted to SEK –18.4 (–8.3) million Period January – June 2017 · Revenues amounted to SEK 0.1 (0.1) million · Operating result amounted to SEK –37.5 (–16.5) million · Result after tax amounted to SEK –37.2 (–17.6) million,